Pancreatic Cancer Research

ResearcherKyoto Prefectural University of MedicineActive in the last 2 years

Takeshi Ishikawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5770-9710; OpenAlex author ID A5025761309. Sources: OpenAlex.

Their work

Papers
9 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. Current status of cancer genome medicine for pancreatic ductal adenocarcinoma. First author DOI 10.1093/jjco/hyaf012↗
  2. Real-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications. First author DOI 10.1111/cas.16329↗
  3. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan. First author DOI 10.1007/s00535-023-01986-9↗
  4. Metformin inhibits TGF‑β1‑induced epithelial‑mesenchymal transition and liver metastasis of pancreatic cancer cells. First author DOI 10.3892/or.2020.7595↗
  5. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Stud… First author DOI 10.1158/2326-6066.cir-17-0386↗
  6. The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. First author DOI 10.3892/or.2017.5399↗
  7. The inhibitory effect of heat treatment against epithelial-mesenchymal transition (EMT) in human pancreatic adenocarcinoma cell lines. First author DOI 10.3164/jcbn.14-8↗
  8. Whole blood interferon-γ levels predict the therapeutic effects of adoptive T-cell therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1002/ijc.28117↗
  9. Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer. Co-author DOI 10.3109/02656736.2012.695428↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshito Itoh · 6 shared papers, 2014–2025 · strength 0.88
  2. Toshifumi Doi · 4 shared papers, 2017–2025 · strength 0.76
  3. Koichi Takayama · 2 shared papers, 2023–2024 · strength 0.33
  4. Tomoki Sakakida · 2 shared papers, 2023–2024 · strength 0.33
  5. Tomohisa Takagi · 5 shared papers, 2012–2020 · strength 0.24
  6. Juichiro Yoshida · 1 shared paper, 2020 · strength 0.09
  7. Masanori Kon · 1 shared paper, 2018 · strength 0.06
  8. Hiroaki Yanagimoto · 1 shared paper, 2018 · strength 0.06
  9. Mari S. Oba · 1 shared paper, 2018 · strength 0.06
  10. Kei Ito · 1 shared paper, 2018 · strength 0.06
  11. Shinichi Egawa · 1 shared paper, 2018 · strength 0.06
  12. Hideaki Shimada · 1 shared paper, 2018 · strength 0.06
  13. Yoshihide Kanno · 1 shared paper, 2018 · strength 0.06
  14. Hidetoshi Eguchi · 1 shared paper, 2018 · strength 0.06
  15. Sadamu Homma · 1 shared paper, 2018 · strength 0.06
  16. Hiroaki Nagano · 1 shared paper, 2018 · strength 0.06
  17. Sumiyuki Nishida · 1 shared paper, 2018 · strength 0.06
  18. Shigeo Koido · 1 shared paper, 2018 · strength 0.06
  19. Michiaki Unno · 1 shared paper, 2018 · strength 0.06
  20. Haruo Sugiyama · 1 shared paper, 2018 · strength 0.06
  21. Toshikazu Yoshikawa · 2 shared papers, 2012–2013 · strength 0.05
  22. Reiko Kimura‐Tsuchiya · 1 shared paper, 2014 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.